Looking back, I see that I have written articles about Sodium Valproate in 2017, 2018 and 2019. To be writing another article today carries mixed emotions: on the one hand satisfaction that this report recognises the errors that have been made and the enormous impact on women and families; but on the other hand it is upsetting to read that some people are still inappropriately prescribed sodium valproate, despite everything that is known about it and the risk of causing avoidable harm.
The ‘First Do No Harm report addresses three medical interventions: sodium valproate, Primodos (a hormone pregnancy test) and pelvic mesh. My colleague, Rankeshwar Batta, has written an article about the report.
The report gathered people’s experiences of sodium valproate and made major recommendations for change to reduce the risk of harm in the future and support to those who have already suffered harm.
In respect of sodium valproate, the report states “We believe that it has taken far too long for serious action to be taken to reduce the number of women who take sodium valproate during pregnancy while unaware of the risk. Women were not given the information they needed to make an informed choice, and despite the efforts of the valproate toolkit and the PPP, too many women still do not have this information.”
Two of the recommendations in respect of sodium valproate are:
On top of the historic and ongoing problems with sodium valproate, the report also identified inadequacies in regulating and monitoring new anti-epileptic drugs. Leading experts and patients raised concerns that the long-term outcomes of the newer generation drugs are unknown. The report recommended a registry for all women on anti-epileptic drugs who become pregnant.
In my work I have spoken with people who were prescribed and still are prescribed sodium valproate. I have heard about the effects it has had on them, their children and even concerns that it might have harmed their grandchildren. As a team we have a wealth of experience working with families of children who have suffered harm resulting in disability from birth. Having seen this from personal experience, I fully support the recommendations in the First Do No Harm report and hope it will improve patient care for other women on anti-epileptic medication in the future.
If you have any questions relating to this e-briefing or epilepsy care, please contact Ann Houghton who will be happy to speak to you on an initial free, no obligation basis.
Epilepsy Society offers a confidential helpline which provides information and emotional support for anyone affected by epilepsy:
01494 601 400 and helpline@epilepsysociety.org.uk
A group of Anthony Collins Solicitors (ACS) experts from across our various client sectors have gazed into their crystal ball and given us a view on how 2021 is looking.
Luton Borough Council was prosecuted by the HSE late last year following an incident at a high school in which an assistant headteacher was attacked by a pupil and left with life-changing injuries.
This ebriefing looks at the proposal to set out 'public procurement principles' in the proposed procurement legislation.
Happy New Year - our first newsletter of 2021! Throughout this year we will continue to bring you news and developments relating to the charities sector.
Local authorities should be wary of reserving contracts for local suppliers, as recommended by Procurement Policy Note (PPN) 11/20. Other contracting authorities may want to maximise their use of this
Most housing practitioners have perhaps been waiting for this news since the latest lockdown was announced by the Prime Minister on 4 January 2021.
Climate change and biodiversity is an area where significantly faster changes are needed on a global and local basis.
Chris Lloyd Smith, Adrian Leonard and Lisa Whitehouse discuss the planning opportunities available to owners of businesses and how to prepare for unforeseen events.
In their 3rd podcast of the series, Chris Lloyd-Smith and Maria Ramon discuss a number of problems with and difficulties that can arise in mediation and the mechanisms they use to overcome them.
Our previous round-up began by sharing the news that two vaccines had shown very promising test results. Here we are, not even a month later, and the first vaccines have already been administered!
To receive invitations to our events, as well as information and articles on legal issues and sector developments that are of interest to you, please sign up to Newsroom.